科伦药业(002422.SZ)：TROP2 ADC芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准第四项适应症上市

Core Viewpoint - The approval of a new indication for the antibody-drug conjugate sac-TMT (also known as SKB264/MK-2870) by the National Medical Products Administration (NMPA) in China represents a significant advancement for the company in the treatment of specific breast cancer patients [1] Group 1: Company Developments - The company’s subsidiary, Sichuan Kelun-Botai Biopharmaceutical Co., Ltd., has received approval for sac-TMT to treat adult patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer who have previously undergone endocrine therapy and at least one line of chemotherapy in advanced disease stages [1] - This new indication marks the fourth approved indication for sac-TMT in China, indicating the drug's expanding therapeutic potential [1]